Azad Surendra, Choudhary Vivek
Department of Radiotherapy, Regional Cancer Centre, Dr BRA M Hospital, Raipur 492 001, Chhattisgarh, India.
J Cancer Res Ther. 2011 Apr-Jun;7(2):157-61. doi: 10.4103/0973-1482.82922.
The aim of this study was to evaluate the response of high dose rate interstitial brachytherapy in carcinoma eye lid.
From January 2004 to December 2008, 20 diagnosed cases of carcinoma eye lid were reported in our department. Lower eye lid was involved in 11 patients and upper eye lid in 9 patients. All cases were staged clinically according to the TNM staging system. All patients were treated with high dose rate interstitial implant and analyzed for presence of residual disease, local recurrence, distant metastasis, radiation reaction and disease free survival.
There was 18 (90%) and 2 (10%) patients in stage I and II, respectively. Histological 10 (50%) cases were of squamous cell carcinoma, 8 (40%) cases were of sebaceous carcinoma and 2 (10%) cases were of basal cell carcinoma. All patients received six fraction of 6.5 Gy in 6 days. Complete response was seen in all patients. The median follow up time for all patients was 39.5 months with 95% confidence interval of 30.1 to 62.6 month. The 5-year disease free survival rate was 90%, 57.14%, and 50% for squamous cell carcinoma, sebaceous cell carcinoma and basal cell carcinoma, respectively. No isolated regional lymph node metastasis and distant metastases were seen. No visual complication was seen.
The results of this study suggest that high dose rate interstitial brachytherapy was appropriate for the treatment of early staged carcinoma of eye lid.
本研究旨在评估高剂量率组织间近距离放射治疗眼睑癌的疗效。
2004年1月至2008年12月,我科共报告20例经诊断的眼睑癌病例。11例累及下眼睑,9例累及上眼睑。所有病例均根据TNM分期系统进行临床分期。所有患者均接受高剂量率组织间植入治疗,并分析残留疾病、局部复发、远处转移、放射反应和无病生存期情况。
I期和II期患者分别有18例(90%)和2例(10%)。组织学类型中,鳞状细胞癌10例(50%),皮脂腺癌8例(40%),基底细胞癌2例(10%)。所有患者在6天内接受6次,每次6.5 Gy的治疗。所有患者均出现完全缓解。所有患者的中位随访时间为39.5个月,95%置信区间为30.1至62.6个月。鳞状细胞癌、皮脂腺癌和基底细胞癌的5年无病生存率分别为90%、57.14%和50%。未发现孤立区域淋巴结转移和远处转移。未出现视力并发症。
本研究结果表明,高剂量率组织间近距离放射治疗适用于早期眼睑癌的治疗。